In this article, we will be taking a look at the 7 Hot Healthcare Stocks to Buy Right Now.
Dr. Warris Bokhari, the CEO and co-founder of Claimable, discussed utilizing AI to fight health insurance denials and other subjects on CNBC’s “Squawk Box” on July 21.
The majority of Americans have experienced the annoyance of having their health insurance rejected, frequently without any recourse after contacting carriers by email and phone. Dr. Bokhari’s technology, which uses artificial intelligence (AI) to challenge care denials for around 70 autoimmune diseases, including Crohn’s disease, has the potential to change this.
After a patient fills out a form, AI handles the next steps, searching for relevant federal and state laws and insurance plans.
Dr. Bokhari claims that the platform was developed following 10 years of monitoring a unique problem facing America: 850 million denials take place each year, and only about 1% of them are ever appealed. These numbers indicate that between 70 and 90 million Americans deal with insurance-related issues annually, such as denials.
The service, which was first introduced in the US on October 2, 2024, helps people appeal care denials for 70 autoimmune conditions by using AI to generate appeal letters based on healthcare plans.
With these trends in mind, let’s look at the hot healthcare stocks to buy right now.
Our Methodology
For our methodology, we first used a screener to filter stocks with a market capitalization exceeding $2 billion and a six-month total return greater than 20%. From this filtered list, we selected the top seven stocks and ranked them in ascending order based on their total returns.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Here is our list of the 7 hot healthcare stocks to buy right now.
7. Qiagen N.V. (NYSE:QGEN)
6 Months Total Return: 20.31%
Qiagen N.V. (NYSE:QGEN), a global leader in molecular diagnostics and sample preparation technologies, continues to advance its position in clinical laboratories, biopharmaceuticals, and life science research. Headquartered in the Netherlands and operating in over 30 countries under CEO Thierry Bernard, the company provides a wide range of solutions, including nucleic acid extraction systems, PCR reagents, digital PCR platforms, next-generation sequencing kits, and proteomics tools. The company stands seventh on our list among the hot stocks to buy.
In Q2 2025, Qiagen N.V. (NYSE:QGEN) reported net sales of $534 million, marking a 7% increase from the prior year, with an adjusted operating income margin of 29.9%, up 1.5 percentage points. Growth was fueled by strong demand for products such as QIAstat-Dx, which grew 41% CER, and QuantiFERON, which increased 11% CER. Reflecting confidence in its operational momentum, the business raised its full-year 2025 net sales growth outlook to 4–5% CER and reaffirmed its adjusted diluted EPS targets.
Innovation remains central to Qiagen N.V. (NYSE:QGEN)’s strategy. The recent launch of QIAseq xHYB Long Read Panels enhances target enrichment for long-read sequencing platforms, enabling more detailed analysis of complex genomic regions, structural variants, HLA typing, and repeat expansions. Additionally, QGEN continues to expand its digital and automation offerings, with growth in QIAcuity digital PCR systems and the QIAGEN Digital Insights software platform, while preparing to launch three new instruments by late 2025 to strengthen its molecular diagnostics capabilities.
6. Humana Inc. (NYSE:HUM)
6 Months Total Return: 20.33%
Humana Inc. (NYSE:HUM), a leading U.S. health insurer, specializes in Medicare Advantage plans, government-sponsored programs, and integrated healthcare services through its insurance and CenterWell health services segments. The company serves millions of Medicare Advantage members and emphasizes value-based care models and coordinated healthcare delivery.
In 2025, Humana Inc. (NYSE:HUM) raised its revenue guidance to at least $128 billion, driven by stronger-than-expected medical cost control and growth in its pharmacy business. This increase reflects the business’s operational resilience amid ongoing challenges in the healthcare insurance sector. A key factor has been the strategic refinement of Medicare Advantage offerings, including plan adjustments in higher-cost counties that reduced the medical loss ratio while retaining more individual members than anticipated.
Humana Inc. (NYSE:HUM)’s CenterWell health services division, encompassing primary care, pharmacy, and home health services, also contributed to growth. Notably, CenterWell Pharmacy’s partnership with Novo Nordisk to sell GLP-1 medications directly to consumers strengthened revenue and diversified HUM’s healthcare delivery capabilities. These initiatives demonstrate the firm’s commitment to expanding beyond traditional insurance into comprehensive healthcare solutions.
5. LeMaitre Vascular, Inc. (NASDAQ:LMAT)
6 Months Total Return: 20.42%
LeMaitre Vascular, Inc. (NASDAQ:LMAT) is a medical device company specializing in products for peripheral vascular disease, affecting over 200 million people worldwide. The company develops and markets disposable and implantable devices used by vascular surgeons, including biologic and biosynthetic grafts, embolectomy and thrombectomy catheters, occlusion and perfusion catheters, and biologic patches for vessel and cardiac repair. Flagship products include the Artegraft biologic graft and Valvulotomes, which support advanced vascular surgeries.
In 2025, LeMaitre Vascular, Inc. (NASDAQ:LMAT) showed strong growth, particularly driven by international sales. Q2 2025 results highlighted that Artegraft sales more than doubled quarter-over-quarter outside the U.S., reflecting growing global adoption. The business continues to expand its footprint across the Americas, Europe, the Middle East, Africa, and Asia Pacific, leveraging a direct sales force and distributor network in over 90 countries. Analysts project revenue growth of 13-15%, fueled by innovative vascular graft products and increasing international penetration, making it one of the hot stocks to buy in the medical device sector.
The corporation focuses on niche vascular device markets valued under $200 million, enabling steady product development with limited competition. Its surgical devices address critical clinical needs, such as bypassing or replacing diseased arteries and improving dialysis access, maintaining relevance in both clinical and commercial settings.
The accelerated adoption of biologic grafts like Artegraft, especially in international markets, underscores LeMaitre Vascular, Inc. (NASDAQ:LMAT)’s momentum in advancing vascular surgery solutions.
4. ResMed Inc. (NYSE:RMD)
6 Months Total Return: 20.75%
ResMed Inc. (NYSE:RMD) is a leading health technology company focused on sleep, breathing, and home care solutions. The company develops innovative devices and digital platforms that support patients with sleep apnea, chronic respiratory conditions, and related disorders, combining medical expertise with advanced technology to improve patient outcomes globally.
In 2025, ResMed Inc. (NYSE:RMD) launched its Sleep Institute, unveiled at the World Sleep Congress, aiming to advance sleep health through partnerships with clinicians, researchers, policymakers, and health system leaders. The initiative focuses on delivering evidence-based insights to drive care innovation and inform policy, addressing the massive global burden of sleep disorders like obstructive sleep apnea (OSA) and insomnia, which remain largely undiagnosed.
The business also highlighted research at the SLEEP 2025 conference, emphasizing trends such as PAP therapy adherence, gender disparities in OSA diagnosis, patient-reported outcomes, and the role of artificial intelligence in enhancing therapy engagement. These developments position RMD as one of the hot stocks to buy in the health technology sector, reflecting its strong growth potential through innovation in both devices and digital health solutions.
Further expanding its capabilities, ResMed Inc. (NYSE:RMD) acquired VirtuOx, an independent diagnostic testing facility specializing in at-home diagnostics for sleep, respiratory, and cardiac conditions. This acquisition strengthens RMD’s ability to provide early diagnosis and connected home-based care, simplifying patient access while supporting better health outcomes.
3. Roivant Sciences Ltd. (NASDAQ:ROIV)
6 Months Total Return: 21.34%
Roivant Sciences Ltd. (NASDAQ:ROIV) is a clinical-stage biopharmaceutical company focused on accelerating the development of medicines and technologies through its network of subsidiaries, or “Vants.” The company specializes in in-licensing promising drug candidates from larger pharmaceutical firms and advancing them toward commercialization. Its current pipeline includes mosliciguat for pulmonary hypertension associated with interstitial lung disease, brepocitinib for inflammatory diseases, and IMVT-1402, a monoclonal antibody targeting autoimmune conditions.
A key recent milestone for Roivant Sciences Ltd. (NASDAQ:ROIV) is the advancement of mosliciguat, an inhaled soluble guanylate cyclase activator. Licensed from Bayer after its exit from respiratory research, mosliciguat has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare, granting regulatory benefits and potential market exclusivity. This positions the business’s Pulmovant subsidiary as a key player in addressing an underserved pulmonary hypertension indication with limited treatment options.
In parallel, Roivant Sciences Ltd. (NASDAQ:ROIV)’s brepocitinib program is progressing toward critical Phase 3 data readouts, supporting ongoing investor and analyst optimism. These advancements, along with ROIV’s strategic focus on rare and immune-mediated diseases, make the company one of the hot stocks to buy for investors seeking high-potential biotech opportunities.
2. Omega Healthcare Investors, Inc. (NYSE:OHI)
6 Months Total Return: 21.68%
Omega Healthcare Investors, Inc. (NYSE:OHI) is a REIT specializing in financing long-term healthcare facilities, including skilled nursing, assisted living, and senior care centers across the U.S. and U.K. As of mid-2025, its portfolio spans over 1,000 facilities operated by nearly 90 healthcare providers, primarily under triple-net lease agreements.
In Q2 2025, Omega Healthcare Investors, Inc. (NYSE:OHI) demonstrated strong portfolio growth and strategic capital deployment, completing $527 million in new investments, including $502 million in real estate acquisitions and $25 million in loans. These moves expanded its skilled nursing and assisted living footprint, generating initial cash yields near 10% with annual escalators of 2-2.5%. The corporation also issued $600 million in senior unsecured notes and extended credit facilities to maintain liquidity and operational flexibility.
The business is increasingly leveraging technology to enhance operator efficiency. Its recent investment in MedaSync, an AI-driven reimbursement optimization platform for skilled nursing facilities, reflects this strategy. MedaSync has rapidly grown its customer base, and OHI’s Senior VP of Operations, Megan Krull, is joining the board, highlighting the strategic importance of this partnership in improving clinical documentation and reimbursement processes.
Active tenant management remains a core focus. Despite challenges like Genesis filing for Chapter 11 in July 2025, Omega Healthcare Investors, Inc. (NYSE:OHI) expects uninterrupted rent payments. It also successfully transitioned another bankrupt tenant’s lease to a new operator, ensuring steady monthly rent streams of approximately $3.1 million. These initiatives demonstrate the company’s proactive approach to risk mitigation and portfolio stability, reinforcing its position as a leading investor in the long-term healthcare sector.
1. Grifols, S.A. (NASDAQ:GRFS)
6 Months Total Return: 21.93%
Grifols, S.A. (NASDAQ:GRFS) tops our list for being one of the hot stocks to buy. It is headquartered in Barcelona and is a global healthcare company specializing in plasma-derived therapies, diagnostics, and hospital supplies. Its main business units, Bioscience, Diagnostics, and Hospital, focus on immunotherapy, transfusion medicine, and critical care, serving patients worldwide with treatments for bleeding disorders, immunodeficiencies, and neurological conditions. The company maintains a strong global presence across 100+ countries and leverages strategic partnerships and acquisitions to drive growth.
In mid-2025, Grifols, S.A. (NASDAQ:GRFS) announced plans to build a new manufacturing site in Spain, aimed at doubling its plasma fractionation capacity in Europe. This expansion reflects the company’s strategic commitment to scaling production capabilities to meet rising demand for plasma-based therapies. The move aligns with GRFS’ Value Creation Plan, which has supported steady revenue growth, including a reported 7% increase to EUR 3,677 million in H1 2025.
The new facility strengthens Grifols, S.A. (NASDAQ:GRFS)’ supply chain resilience and positions the company competitively in the growing plasma therapeutics market. By expanding production, the business aims to improve market share while addressing critical clinical needs in immunotherapy and transfusion medicine.
While we acknowledge the potential of GRFS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GRFS and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
